Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Long-Term Investments: 2020-2025

Historic Long-Term Investments for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $473.1 million.

  • Kymera Therapeutics' Long-Term Investments rose 31.04% to $473.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.1 million, marking a year-over-year increase of 31.04%. This contributed to the annual value of $362.2 million for FY2024, which is 489.58% up from last year.
  • Per Kymera Therapeutics' latest filing, its Long-Term Investments stood at $473.1 million for Q3 2025, which was up 58.96% from $297.6 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Long-Term Investments peaked at $473.1 million during Q3 2025, and registered a low of $45.3 million during Q2 2021.
  • Its 3-year average for Long-Term Investments is $229.8 million, with a median of $224.4 million in 2024.
  • Its Long-Term Investments has fluctuated over the past 5 years, first tumbled by 60.15% in 2021, then soared by 489.58% in 2024.
  • Kymera Therapeutics' Long-Term Investments (Quarterly) stood at $125.2 million in 2021, then increased by 21.67% to $152.3 million in 2022, then plummeted by 59.67% to $61.4 million in 2023, then soared by 489.58% to $362.2 million in 2024, then spiked by 31.04% to $473.1 million in 2025.
  • Its Long-Term Investments stands at $473.1 million for Q3 2025, versus $297.6 million for Q2 2025 and $312.3 million for Q1 2025.